Your browser doesn't support javascript.
loading
Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.
Khitri, Mohamed-Yacine; Guedon, Alexis F; Georgin-Lavialle, Sophie; Terrier, Benjamin; Saadoun, David; Seguier, Julie; le Besnerais, Maelle; De Moreuil, Claire; Denis, Guillaume; Gerfaud-Valentin, Mathieu; Allain, Jean Sebastien; Maria, Alexandre; Bouillet, Laurence; Grobost, Vincent; Galland, Joris; Kosmider, Olivier; Dumont, Anael; Devaux, Mathilde; Subran, Benjamin; Schmidt, Jean; Marianetti-Guingel, Paola; Audia, Sylvain; Palat, Sylvain; Roux-Sauvat, Marielle; Jachiet, Vincent; Hirsch, Pierre; Fain, Olivier; Mekinian, Arsène.
Afiliação
  • Khitri MY; Hopital Saint-Antoine Service de Medecine Interne, Paris, Île-de-France, France.
  • Guedon AF; Pierre Louis Epidemiology and Public Health Research Institute, Paris, Île-de-France, France.
  • Georgin-Lavialle S; Tenon Hospital, Internal Medicine, AP-HP, Paris, France.
  • Terrier B; France.
  • Saadoun D; Hopital Cochin, Paris, Île-de-France, France.
  • Seguier J; Hopital Universitaire Pitie Salpetriere, Paris, Île-de-France, France.
  • le Besnerais M; Hospital Timone, Marseille, Provence-Alpes-Côte d'Azu, France.
  • De Moreuil C; Hôpital Charles Nicolle, Rouen, Normandy, France.
  • Denis G; CHRU de Brest, Brest, Bretagne, France.
  • Gerfaud-Valentin M; Centre Hospitalier de Rochefort, Rochefort, Nouvelle-Aquitaine, France.
  • Allain JS; University Hospital Centre Lyon, Lyon, Auvergne-Rhône-Alpes, France.
  • Maria A; CHU Rennes, Rennes, Bretagne, France.
  • Bouillet L; CHU Montpellier, Montpellier, Languedoc-Roussillon, France.
  • Grobost V; Internal Medicine, Centre Hospitalier Universitaire Grenoble, Michallon Hospital, Grenoble, France.
  • Galland J; CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Kosmider O; Hospital Centre Fleyriat de Bourg-en-Bresse, Bourg-en-Bresse, Rhône-Alpes, France.
  • Dumont A; Service d'Hématologie Biologique, DMU BioPhyGen, APHP, Paris, Île-de-France, France.
  • Devaux M; CHU Caen, Caen, Basse-Normandie, France.
  • Subran B; Intermunicipal Hospital Centre Poissy-Saint-Germain-en-Laye Poissy Site, Poissy, Île-de-France, France.
  • Schmidt J; Hôpital de la Croix Saint-Simon, Paris, Île-de-France, France.
  • Marianetti-Guingel P; Internal Medicine, Amiens University Hospital, Amiens, France.
  • Audia S; CHU Reims, Reims, Champagne-Ardenne, France.
  • Palat S; CHU Dijon, Dijon, Bourgogne, France.
  • Roux-Sauvat M; CHU Limoges, Limoges, Limousin, France.
  • Jachiet V; Service de médecine interne, Pierre Oudot Hospital of Bourgoin-Jallieu, Bourgoin-Jallieu, Rhône-Alpes, France.
  • Hirsch P; Hopital Saint-Antoine Service de Medecine Interne, Paris, Île-de-France, France.
  • Fain O; service d'hématologie biologique, Hôpital Saint-Antoine, Paris, Île-de-France, France.
  • Mekinian A; Hopital Saint-Antoine Service de Medecine Interne, Paris, Île-de-France, France.
RMD Open ; 8(2)2022 07.
Article em En | MEDLINE | ID: mdl-35868738
OBJECTIVE: A new adult-onset autoinflammatory syndrome has been described, named VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic). We aimed to compare the clinical characteristics, the laboratory features and the outcomes between idiopathic-relapsing polychondritis (I-RP) and VEXAS-relapsing polychondritis (VEXAS-RP). METHODS: Patients from French retrospective multicentre cohort of RP were separated into two groups: a VEXAS-RP and an I-RP. RESULTS: Compared with patients with I-RP (n=40), patients with VEXAS-RP (n=55) were men (96% vs 30%, p<0.001) and were older at diagnosis (66 vs 44 years, p<0.001). They had a greater prevalence of fever (60% vs 10%, p<0.001), of skin lesions (82% vs 20%, p<0.001), of ocular involvement (57% vs 28%, p=0.01), of pulmonary infiltrates (46% vs 0%, p<0.001), of heart involvement (11% vs 0%, p=0.0336) and with higher median C-reactive protein levels (64 mg/L vs 10 mg/L, p<0.001). Seventy-five per cent of the patients with VEXAS-RP had myelodysplastic syndrome (MDS) versus none in I-RP group. The glucocorticoids use, and the number of steroid sparing agents were similar in both groups, but patients with VEXAS-RP had more frequent refractory disease (remission obtained in 27% vs 90%, p<0001). VEXAS-RP was associated with higher risk of death: six patients (11%) died in the VEXAS-RP group after a median follow-up of 37 months and none in the I-RP group after a median follow-up of 92 months (p<0.05). CONCLUSION: We report the largest cohort of VEXAS-RP, characterised by high prevalence of male sex, fever, skin lesion, ocular involvement, pulmonary infiltration, heart involvement, older age and MDS association.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Policondrite Recidivante / Síndromes Mielodisplásicas Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: RMD Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Policondrite Recidivante / Síndromes Mielodisplásicas Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: RMD Open Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França País de publicação: Reino Unido